What The AbbVie Decision Says About Sham Patent Cases
By Leslie John and Stephen Kastenberg ( July 3, 2018, 5:07 PM EDT) -- The decision last Friday by Judge Harvey Bartle of the United States District Court for the Eastern District of Pennsylvania — holding that AbbVie Inc. and its partner Besins Healthcare Inc. blocked the market entry of a generic competitor and ordering the companies to disgorge $448 million in profits — is likely to have significant effects on antitrust cases challenging patent litigations as shams and how they are litigated....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.